Recent findings concerning the combination of PD-1/PD-L1 blockers with front-line chemotherapy in advanced NSCLC patients compared to the same chemotherapy doublet alone were partially sorrowed by the occurrence of a high risk of early deaths (within 60 days of treatment) due to severe immunological disorders [45,46]. Here, CD274 is linked to non-small cell lung carcinoma.